OA09124A - Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis. - Google Patents

Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis.

Info

Publication number
OA09124A
OA09124A OA59616A OA59616A OA09124A OA 09124 A OA09124 A OA 09124A OA 59616 A OA59616 A OA 59616A OA 59616 A OA59616 A OA 59616A OA 09124 A OA09124 A OA 09124A
Authority
OA
OAPI
Prior art keywords
preparation
immunomodulatory
medicaments
intended
acquired immunodeficiency
Prior art date
Application number
OA59616A
Other languages
English (en)
French (fr)
Inventor
Shelly Marc Yves Franc Clement
Original Assignee
Shelly Marc Yves Franck Clemen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shelly Marc Yves Franck Clemen filed Critical Shelly Marc Yves Franck Clemen
Publication of OA09124A publication Critical patent/OA09124A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA59616A 1987-01-21 1989-07-20 Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis. OA09124A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8700670A FR2609632B1 (fr) 1987-01-21 1987-01-21 Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage

Publications (1)

Publication Number Publication Date
OA09124A true OA09124A (fr) 1991-10-31

Family

ID=9347124

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59616A OA09124A (fr) 1987-01-21 1989-07-20 Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis.

Country Status (9)

Country Link
EP (1) EP0278821B1 (da)
JP (1) JPH02502278A (da)
AT (1) ATE112488T1 (da)
AU (1) AU610561B2 (da)
DE (1) DE3851711D1 (da)
DK (1) DK524788A (da)
FR (1) FR2609632B1 (da)
OA (1) OA09124A (da)
WO (1) WO1988005297A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
RU2056852C1 (ru) * 1994-03-18 1996-03-27 Иван Николаевич Головистиков Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
RU2058553C1 (ru) * 1994-03-18 1996-04-20 Иван Николаевич Головистиков Способ определения супрессорного звена иммунного статуса человека
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
MXPA04008772A (es) * 2002-03-14 2004-12-06 Euro Celtique Sa Composiciones de clorhidrato de naltrexona.
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP3064503A1 (en) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2017141104A2 (en) * 2016-02-18 2017-08-24 Immune Therapeutics, Inc. Method for inducing a sustained immune response
EP3937972A4 (en) * 2019-03-13 2023-01-04 Adamis Pharmaceuticals Corporation FORMULATION COMPRISING A COMBINATION OF BETA-ENDORPHIN AND ADRENOCORTICOTROPIC HORMONE
US11285192B2 (en) 2019-03-13 2022-03-29 Adamis Pharmaceuticals Corporation Formulation including a combination of beta-endorphin and adrenocorticotropic hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Also Published As

Publication number Publication date
WO1988005297A1 (fr) 1988-07-28
AU610561B2 (en) 1991-05-23
DK524788D0 (da) 1988-09-21
DE3851711D1 (de) 1994-11-10
EP0278821B1 (fr) 1994-10-05
EP0278821A1 (fr) 1988-08-17
JPH02502278A (ja) 1990-07-26
ATE112488T1 (de) 1994-10-15
DK524788A (da) 1988-11-18
AU1189688A (en) 1988-08-10
FR2609632A1 (fr) 1988-07-22
FR2609632B1 (fr) 1991-03-29

Similar Documents

Publication Publication Date Title
OA09124A (fr) Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis.
FR2615394B1 (fr) Utilisation de certains 17-cetosteroides, eventuellement avec un immunomodulateur et/ou un agent antiviral, pour fabriquer un medicament pour le traitement et la prevention des infections retrovirales
FI862011A0 (fi) Terapeutiska nukleosider.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
NO871549D0 (no) Medikament for behandling av oeyenbetennelser.
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
SE8704298D0 (sv) Compounds for use in therapy
DE69129800D1 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
ATE190064T1 (de) Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
NO922936D0 (no) Fremstilling av fettsyremedikamenter
ATE100098T1 (de) Nukleoside, ihre herstellung und pharmazeutische zusammenstellungen.
ZA90245B (en) Treatment of diseases associated with hiv infections
ATE77554T1 (de) Pharmazeutisches praeparat mit 3'-desoxythymidin2'-en(3'-desoxy-2',3'-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen.
DE3873327D1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
DK538888A (da) Anvendelse af castanosperminestere til fremstilling af et farmaceutisk praeparat
ATE82294T1 (de) Therapeutische nukleoside.
ES2108680T3 (es) Uso del derivado n-n-butilo de desoxinojirimicina en la fabricacion de un medicamento.
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
FR2361109A1 (fr) Medicaments anthelminthiques
IT1225262B (it) Metodo per la sensibilizzazione di piccoli animali all'infezione da virus dell'immunodeficienza umana (hiv)
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
ATE84418T1 (de) 2,6-diamino-3-phenyl-azo-pyridin enthaltendes tier- und humanarzneimittel mit antiviraler und antitumoraler aktivitaet.
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
ZA901992B (en) Antiviral compositions